Krisv Kowdley News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

Bexotegrast at 320 mg was well tolerated over 12 weeks of treatment with no drug-related severe or serious adverse events; No safety concerns identified across all dose cohorts Bexotegrast at 320.

United statesGideon hirshfieldClin gastroenterol hepatolKrisv kowdleyChristopher keenanTerry hornerWashington state universityElsons floyd college of medicineCorporate communicationsDrug administrationLiver instituteEuropean medicines agencyPliant therapeutics incUniversity of torontoClinical development nextGlobenewswire inc

Pliant Therapeutics Announces Positive Safety and

Bexotegrast (PLN-74809) at 320 mg was well tolerated over 12 weeks of treatment with no drug-related severe or serious adverse events; No safety concerns.

United statesGideon hirshfieldChristopher keenanClin gastroenterol hepatolTerry hornerKrisv kowdleyUniversity of torontoCorporate communicationsLiver instituteClinical development nextDrug administrationEuropean medicines agencyPliant therapeutics incEnhanced liver fibrosisChief medical officerWell tolerated

Pliant Therapeutics Announces Positive Safety And Exploratory Efficacy Data From The INTEGRIS-PSC Phase 2A Trial Of Bexotegrast 320 Mg In Patients Wit

Pliant Therapeutics Announces Positive Safety And Exploratory Efficacy Data From The INTEGRIS-PSC Phase 2A Trial Of Bexotegrast 320 Mg In Patients Wit
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

United statesClin gastroenterol hepatolTerry hornerChristopher keenanKrisv kowdleyGideon hirshfieldPliant therapeutics incEuropean medicines agencyDrug administrationCorporate communicationsUniversity of torontoLiver instituteClinical development nextEnhanced liver fibrosisChief medical officerWell tolerated

Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesKrisv kowdleyGideon hirshfieldClin gastroenterol hepatolChristopher keenanTerry hornerDrug administrationEuropean medicines agencyClinical development nextUniversity of torontoPliant therapeutics incLiver instituteCorporate communicationsEnhanced liver fibrosisChief medical officerWell tolerated

Clinical trial results suggest potential new treatment for primary biliary cholangitis

Clinical trial results suggest potential new treatment for primary biliary cholangitis
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

United statesKrisv kowdleyChristopher bowlusUc davis healthNew england journalLiver meetingAmerican associationPrimary biliary cholangitis